Patents Assigned to VentiRx Pharmaceuticals, Inc.
-
Patent number: 10016440Abstract: The application relates to method of increasing antibody-dependent cellular cytotoxicity in a subject receiving therapeutic monoclonal antibody treatment. In some embodiments, methods are provided for administering to subject to a subject in need thereof a therapeutic antibody in conjunction with an ADCC enhancer molecule.Type: GrantFiled: April 21, 2011Date of Patent: July 10, 2018Assignee: VentiRx Pharmaceuticals, Inc.Inventor: Robert Hershberg
-
Patent number: 9718796Abstract: Provided are compositions and methods useful for modulation of signaling through the Toll-like receptors TLR7 and/or TLR8. The compositions and methods have use in treating or preventing disease, including cancer, autoimmune disease, fibrotic disease, cardiovascular disease, infectious disease, inflammatory disorder, graft rejection, or graft-versus-host disease.Type: GrantFiled: January 12, 2012Date of Patent: August 1, 2017Assignees: VENTIRX PHARMACEUTICALS, INC., ARRAY BIOPHARMA, INC.Inventors: James Jeffry Howbert, Robert Hershberg, Laurence E. Burgess, Hong Woon Yang
-
Patent number: 9655904Abstract: Provided are compositions and methods useful for modulation of signaling through the Toll-like receptors TLR7 and/or TLR8. The compositions and methods have use in treating or preventing disease, including cancer, autoimmune disease, infectious disease, inflammatory disorder, graft rejection, and graft-versus-host disease.Type: GrantFiled: August 4, 2015Date of Patent: May 23, 2017Assignees: VENTIRX PHARMACEUTICALS, INC., ARRAY BIOPHARMA, INC.Inventors: James Jeffry Howbert, Gregory Dietsch, Robert Hershberg, Laurence E. Burgess, Joseph P. Lyssikatos, Brad Newhouse, Hong-Woon Yang
-
Publication number: 20160137608Abstract: Provided are compositions and methods useful for modulation of signaling through the Toll-like receptors TLR7 and/or TLR8. The compositions and methods have use in treating or preventing disease, including cancer, autoimmune disease, infectious disease, inflammatory disorder, graft rejection, and graft-verses-host disease.Type: ApplicationFiled: October 13, 2015Publication date: May 19, 2016Applicants: VENTIRX PHARMACEUTICALS, INC., ARRAY BIOPHARMA, INC.Inventors: James Jeffry Howbert, Gregory N. Dietsch, Robert Hershberg, Laurence E. Burgess, George A. Doherty, C. Todd Eary, Robert D. Groneberg, Zachery Jones
-
Patent number: 9242964Abstract: Provided are compositions and methods useful for modulation of signaling through the Toll-like receptors TLR7 and/or TLR8. The compositions and methods have use in treating or preventing disease, including cancer, autoimmune disease, infectious disease, inflammatory disorder, graft rejection, and graft-verses-host disease.Type: GrantFiled: September 3, 2013Date of Patent: January 26, 2016Assignees: VENTIRX PHARMACEUTICALS, INC., ARRAY BIOPHARMA, INC.Inventors: James Jeffry Howbert, Gregory Dietsch, Robert M. Hershberg, Laurence E. Burgess, George A. Doherty, C. Todd Eary, Robert D. Groneberg, Zachary Jones
-
Patent number: 9216192Abstract: The present invention is directed generally to stable formulations of a TLR agonist preferably a TLR7 or a TLR8 agonist, for use in the treatment of cancer, preferably solid tumors and lymphomas. Specifically, the present invention is directed to stable formulations of up to 50 mg/ml of a TLR agonist which comprise a cyclodextrin.Type: GrantFiled: July 16, 2012Date of Patent: December 22, 2015Assignee: VentiRx Pharmaceuticals, Inc.Inventors: J. Jeffry Howbert, Muralikrishna Duvvuri, Robert Hershberg, Gregory Dietsch
-
Patent number: 9126940Abstract: Provided are compositions and methods useful for modulation of signaling through the Toll-like receptors TLR7 and/or TLR8. The compositions and methods have use in treating or preventing disease, including cancer, autoimmune disease, infectious disease, inflammatory disorder, graft rejection, and graft-verses-host disease.Type: GrantFiled: February 14, 2014Date of Patent: September 8, 2015Assignees: VentiRx Pharmaceuticals, Inc., Array Biopharma, Inc.Inventors: James Jeffry Howbert, Gregory Dietsch, Robert Hershberg, Laurence E. Burgess, Joseph P. Lyssikatos, Brad Newhouse, Hong-Woon Yang
-
Publication number: 20140234376Abstract: Provided are compositions and methods useful for modulation of signaling through the Toll-like receptors TLR7 and/or TLR8. The compositions and methods have use in treating or preventing disease, including cancer, autoimmune disease, infectious disease, inflammatory disorder, graft rejection, and graft-verses-host disease.Type: ApplicationFiled: February 14, 2014Publication date: August 21, 2014Applicants: Array BioPharma, Inc., VentiRx Pharmaceuticals, Inc.Inventors: James Jeffry Howbert, Gregory Dietsch, Robert Hershberg, Laurence E. Burgess, Joseph P. Lyssikatos, Brad Newhouse, Hong-Woon Yang
-
Publication number: 20140142086Abstract: Provided are compositions and methods useful for modulation of signaling through the Toll-like receptors TLR7 and/or TLR8. The compositions and methods have use in treating or preventing disease, including cancer, autoimmune disease, infectious disease, inflammatory disorder, graft rejection, and graft-verses-host disease.Type: ApplicationFiled: September 3, 2013Publication date: May 22, 2014Applicants: ARRAY BIOPHARMA, INC., VENTIRX PHARMACEUTICALS, INC.Inventors: James Jeffry Howbert, Gregory Dietsch, Robert M. Hershberg, Laurence E. Burgess, George A. Doherty, C. Todd Eary, Robert D. Groneberg, Zachary Jones
-
Patent number: 8691809Abstract: Provided are compositions and methods useful for modulation of signaling through the Toll-like receptors TLR7 and/or TLR8. The compositions and methods have use in treating or preventing disease, including cancer, autoimmune disease, infectious disease, inflammatory disorder, graft rejection, and graft-verses-host disease.Type: GrantFiled: August 18, 2010Date of Patent: April 8, 2014Assignees: VentiRx Pharmaceuticals, Inc., Array BioPharma, Inc.Inventors: James Jeffry Howbert, Gregory Dietsch, Robert Hershberg, Laurence E. Burgess, Joseph P. Lyssikatos, Brad Newhouse, Hong Woon Yang
-
Publication number: 20140088085Abstract: Provided are compositions and methods useful for modulation of signaling through the Toll-like receptors TLR7 and/or TLR8. The compositions and methods have use in treating or preventing disease, including cancer, autoimmune disease, fibrotic disease, cardiovascular disease, infectious disease, inflammatory disorder, graft rejection, or graft-versus-host disease.Type: ApplicationFiled: January 12, 2012Publication date: March 27, 2014Applicants: ARRAY BIOPHARMA, INC, VENTIRX PHARMACEUTICALS, INCInventors: Laurence E. Burgess, George A. Doherty, C. Todd Eary, Robert D. Groneberg, Zachary Jones, James Jeffry Howbert, Robert Hershberg, Joseph P. Lyssikatos, Hong Woon Yang
-
Publication number: 20130236449Abstract: The application relates to method of increasing antibody-dependent cellular cytotoxicity in a subject receiving therapeutic monoclonal antibody treatment. In some embodiments, methods are provided for administering to subject to a subject in need thereof a therapeutic antibody in conjunction with an ADCC enhancer molecule.Type: ApplicationFiled: April 21, 2011Publication date: September 12, 2013Applicant: VENTIRX PHARMACEUTICALS, INC.Inventor: Robert Hershberg
-
Patent number: 8524702Abstract: Provided are compositions and methods useful for modulation of signaling through the Toll-like receptors TLR7 and/or TLR8. The compositions and methods have use in treating or preventing disease, including cancer, autoimmune disease, infectious disease, inflammatory disorder, graft rejection, and graft-verses-host disease.Type: GrantFiled: August 18, 2010Date of Patent: September 3, 2013Assignees: VentiRx Pharmaceuticals, Inc., Array BioPharma, Inc.Inventors: James Jeffry Howbert, Gregory Dietsch, Robert Hershberg, Laurence E. Burgess, George A. Doherty, C. Todd Eary, Robert D. Groneberg, Zachary Jones
-
Patent number: 8314090Abstract: The disclosure describes method of synthesis of substituted benzazepine derivatives. Preferred methods according to the disclosure allow for large-scale preparation of benzazepine compounds having low levels of metal impurities. In some embodiments, preferred methods according to the disclosure also allow for the preparation of benzazepine derivatives without the use of chromatographic purification methods and in better yield than previously used methods for preparing such compounds. The methods disclosed herein find utility in synthetic organic chemistry as well as medicinal chemistry.Type: GrantFiled: November 6, 2009Date of Patent: November 20, 2012Assignees: VentiRx Pharmaceuticals, Inc., Array BioPharma, Inc.Inventors: J. Jeffry Howbert, Venkat Reddy Kusukuntla, Alexander Tretyakov, Nathan Nielsen, Pavel Krasik, Ji-Long Jiang, Hong Woon Yang
-
Publication number: 20120219615Abstract: The present invention is directed generally to formulations of a TLR agonist preferably a TLR8 agonist, and its use in the treatment of various diseases, including combination therapies for treating cancer.Type: ApplicationFiled: October 3, 2011Publication date: August 30, 2012Applicants: The Trustees of the University of Pennsylvania, VentiRx Pharmaceuticals, Inc.Inventors: Robert Hershberg, George Coukos, Gregory Dietsch, Andrea Facciabene, Kristi Manjarrez, Tressa D. Randall
-
Patent number: 8242106Abstract: The present invention is directed generally to stable formulations of a TLR agonist preferably a TLR7 or a TLR8 agonist, for use in the treatment of cancer, preferably solid tumors and lymphomas. Specifically, the present invention is directed to stable formulations of up to 50 mg/ml of a TLR agonist which comprise a cyclodextrin.Type: GrantFiled: July 31, 2009Date of Patent: August 14, 2012Assignee: VentiRx Pharmaceuticals, Inc.Inventors: J. Jeffry Howbert, Muralikrishna Duvvuri, Robert Hershberg, Gregory Dietsch
-
Publication number: 20120082658Abstract: The present invention is directed generally to a TLR8 agonist VTX-378, for use in the treatment or prevention of allergic diseases, including allergic rhinitis.Type: ApplicationFiled: October 3, 2011Publication date: April 5, 2012Applicant: VentiRx Pharmaceuticals, Inc.Inventor: Robert Hershberg
-
Publication number: 20110118235Abstract: Provided are compositions and methods useful for modulation of signaling through the Toll-like receptors TLR7 and/or TLR8. The compositions and methods have use in treating or preventing disease, including cancer, autoimmune disease, infectious disease, inflammatory disorder, graft rejection, and graft-verses-host disease.Type: ApplicationFiled: August 18, 2010Publication date: May 19, 2011Applicants: VentiRx Pharmaceuticals, Inc., Array BioPharma, Inc.Inventors: James Jeffry Howbert, Gregory Dietsch, Robert Hershberg, Laurence E. Burgess, George A. Doherty, C. Todd Eary, Robert D. Groneberg, Zachary Jones
-
Publication number: 20110092485Abstract: Provided are compositions and methods useful for modulation of signaling through the Toll-like receptors TLR7 and/or TLR8. The compositions and methods have use in treating or preventing disease, including cancer, autoimmune disease, infectious disease, inflammatory disorder, graft rejection, and graft-verses-host disease.Type: ApplicationFiled: August 18, 2010Publication date: April 21, 2011Applicants: VentiRx Pharmaceuticals, Inc., Array BioPharma, Inc.Inventors: James Jeffry Howbert, Gregory Dietsch, Robert Hershberg, Laurence E. Burgess, Joseph P. Lyssikatos, Brad Newhouse, Hong Woon Yang
-
Publication number: 20100216989Abstract: The disclosure describes method of synthesis of substituted benzazepine derivatives. Preferred methods according to the disclosure allow for large-scale preparation of benzazepine compounds having low levels of metal impurities. In some embodiments, preferred methods according to the disclosure also allow for the preparation of benzazepine derivatives without the use of chromatographic purification methods and in better yield than previously used methods for preparing such compounds. The methods disclosed herein find utility in synthetic organic chemistry as well as medicinal chemistry.Type: ApplicationFiled: November 6, 2009Publication date: August 26, 2010Applicants: VentiRx Pharmaceuticals, Inc., Array BioPharma, Inc.Inventors: J. Jeffry Howbert, Venkat R. Kusukuntla, Alexander Tretyakov, Nathan Nielsen, Pavel Krasik, Ji-Long Jiang, Hong Woon Yang